A global perspective: characteristics of infertility‐related randomized clinical trials

Author:

Xi Yu12,Cao Ya‐Lei12,Tao Li‐Yuan34,Gao Song‐Zhan5,Jin Zi‐Run12,Cheng Jian‐Xing12,Jiang Hui67ORCID,Zhang Zhe12ORCID

Affiliation:

1. Department of Urology Peking University Third Hospital Beijing China

2. Department of Reproductive Medicine Center Peking University Third Hospital Beijing China

3. Department of Epidemiology Harvard T.H. Chan School of Public Health Boston Massachusetts USA

4. Research Center of Clinical Epidemiology Peking University Third Hospital Beijing China

5. Department of Andrology Third Affiliated Hospital of Zhengzhou University Zhengzhou China

6. Department of Urology Peking University First Hospital Beijing China

7. Institute of Urology Peking University Beijing China

Abstract

AbstractBackgroundInfertility is a prevalent global condition, and emerging reproductive technologies may enhance its evaluation and treatment. Understanding the current features of randomized clinical trials in infertility is crucial for improving study design and ensuring the translation of results for patient benefits.ObjectivesTo investigate the primary characteristics of randomized clinical trials related to infertility and areas where require improvement.Materials and methodsWe conducted a search on the International Clinical Trials Registry platform for eligible infertility trials between 2003 and 2022. The distribution ratio of various characteristics uploaded by infertility‐related studies on the platform was analyzed and compared according to sex and registration year.ResultsOut of the total trials, 85.3% (1,906) included only women, 8.6% (192) included only men, and 6.1% (136) included couples. The majority of retrieved trials followed a parallel arm design (91.0%) and were non‐industry‐funded (92.2%), with a median planned sample size of 131 patients (interquartile range 75–270). Among these trials, 54.5% (1,217) were conducted in Asia. The most common primary purpose of infertility‐related trials was treatment (88.8%), with over half of the investigated interventions focusing on medication (57.9%).DiscussionAsia is the leading region for research, and the drug therapy is still widely used and updated. However, support care for infertile couples has also received some preference. Areas that require improvement and promotion include addressing male infertility and focusing on underserved regions like Africa. The results also highlight deficiencies in trial registration and masking methods, emphasizing the need for better regulation and facilitation of infertility trials in the post‐COVID‐19 era.ConclusionBased on the current status of infertility RCT studies, greater attention should be paid to infertile men and populations in underdeveloped regions like Africa in future studies, together with a standardized registration and implementation procedures.

Funder

Natural Science Foundation of Beijing Municipality

National Natural Science Foundation of China

Publisher

Wiley

Subject

Urology,Endocrinology,Reproductive Medicine,Endocrinology, Diabetes and Metabolism

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3